Your browser doesn't support javascript.
loading
Interventions to Improve Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review.
Heiney, Sue P; Sorrell, McKenzie; Sheng, Jingxi; Adams, Swann A; Nelson, Kathy; Nguyen, Lan A; Edwards, Amy; Wickersham, Karen E.
Afiliação
  • Heiney SP; College of Nursing.
  • Sorrell M; Prisma Health-Midlands/USC School of Medicine Columbia, Internal Medicine Residency Program.
  • Sheng J; Medical University of South Carolina, Charleston, SC.
  • Adams SA; College of Nursing.
  • Nelson K; College of Nursing.
  • Nguyen LA; Department of Epidemiology & Biostatistics, Arnold School of Public Health.
  • Edwards A; College of Nursing.
  • Wickersham KE; College of Nursing.
Am J Clin Oncol ; 44(6): 291-298, 2021 06 01.
Article em En | MEDLINE | ID: mdl-33867480
BACKGROUND: Lack of adherence to tyrosine kinase inhibitors (TKIs) is a significant problem resulting in incomplete cytogenetic response and increased mortality in patients with chronic myeloid leukemia (CML). Few studies have been conducted on interventions to improve adherence. The authors conducted a systematic review to explore studies that examined the impact of strategies to improve TKI adherence among individuals with CML. METHODS: The first 2 authors completed a systematic literature review according to the guidelines in Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA). Studies (n=2633) conducted between 1980 and 2019 were identified through 3 databases and examined for inclusion/exclusion criteria. RESULTS: Fourteen studies were identified which met the eligibility criteria. The studies only examined adherence to imatinib, dasatinib, or nilotinib. Ten of the 14 used large data sets (commercial health insurance plans or Surveillance Epidemiology and End Results [SEER] data) for analysis. The majority of the studies used a cohort design. Adherence was defined and measured in a variety of ways with most studies using 80% or higher as adequate adherence. Strategies not focused on health care costs used a multidisciplinary team approach. CONCLUSION: Development of evidence to improve treatment adherence to TKIs for CML have relied on large data sets rather than prospective trials. Current studies lack patient focused interventions.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva / Custos de Cuidados de Saúde / Inibidores de Proteínas Quinases / Adesão à Medicação Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva / Custos de Cuidados de Saúde / Inibidores de Proteínas Quinases / Adesão à Medicação Idioma: En Ano de publicação: 2021 Tipo de documento: Article